microbiolog
acut
otiti
media
aom
link
nasopharyng
commens
flora
respiratori
ecosystem
undergo
variou
select
pressur
antibiot
consumpt
vaccin
use
socioeconom
condit
also
influenc
bacteri
composit
nasopharynx
streptococcu
pneumonia
nonencapsul
haemophilu
influenza
moraxella
catarrhali
group
streptococcu
lead
caus
bacteri
aom
worldwid
paper
discuss
caus
consequ
recent
shift
underli
microbiolog
aom
otiti
media
om
common
childhood
diseas
major
concern
paediatrician
prospect
studi
perform
usa
three
quarter
children
complet
investig
experienc
least
one
episod
acut
om
aom
age
year
suffer
least
three
episod
center
diseas
control
prevent
estim
om
account
million
physician
visit
per
annum
usa
furthermor
recent
multin
survey
paediatrician
report
saw
least
one
patient
om
per
day
aom
often
preced
viral
upper
respiratori
tract
infect
urti
common
infecti
ill
gener
popul
common
ill
children
prospect
studi
follow
children
age
month
year
total
urti
record
aom
report
children
cours
viral
infect
ie
episod
aom
per
child
per
year
underli
microbiolog
infecti
diseas
known
chang
respons
environment
factor
vaccin
antibiot
consumpt
exampl
epidemiolog
bacteri
mening
chang
countri
haemophilu
influenza
type
b
group
c
meningococc
pneumococc
conjug
vaccin
introduc
dramat
reduct
incid
bacteri
mening
overal
howev
nonvaccin
serotyp
streptococcu
pneumonia
account
signific
proport
diseas
countri
tel
fax
email
address
annevergison
ulbacb
annevergison
huderfb
sevenval
pneumococc
conjug
vaccin
prevnar
tm
prevenar
wide
use
furthermor
pneumonia
isol
reduc
suscept
penicillin
recov
human
infect
late
australia
new
guinea
sinc
penicillin
nonsuscept
pneumonia
strain
spread
world
preval
dramat
increas
variou
countri
moreov
pneumonia
accumul
multipl
resist
determin
strain
serotyp
modifi
epidemiolog
landscap
region
includ
usa
although
region
penicillin
remain
activ
pneumonia
despit
increas
minim
inhibitori
concentr
use
safe
treat
pneumococc
infect
mening
multiresist
strain
describ
infect
aom
recent
report
usa
present
nine
clinic
failur
aom
due
pneumonia
resist
amoxicillin
oral
cephalosporin
macrolid
clindamycin
cotrimoxazol
requir
tube
placement
drainag
use
levofloxacin
drug
licens
paediatr
use
anoth
recent
us
studi
increas
proport
sever
mastoid
case
observ
mostli
due
multiresist
serotyp
pneumonia
begin
centuri
group
streptococcu
ga
common
pathogen
lead
complic
aom
rare
western
world
new
triad
aom
pathogen
emerg
last
centuri
pneumonia
nonencapsul
h
influenza
often
call
nontyp
h
influenza
nthi
moraxella
catarrhali
commens
bacteria
found
human
nasopharynx
review
provid
insight
microbiolog
aom
era
antibiot
resist
pneumococc
conjug
vaccin
use
aom
multipathogen
diseas
caus
number
differ
virus
bacteria
virus
alon
found
case
coinfect
bacteria
seen
case
among
virus
coronaviru
respiratori
syncyti
viru
adenoviru
commonli
associ
aom
pneumonia
h
influenza
far
common
bacteri
pathogen
aom
recov
case
catarrhali
usual
third
frequent
bacterium
isol
ga
make
case
although
incid
ga
infect
differ
countri
depend
studi
perform
whether
sever
case
aom
includ
fig
diagnosi
aom
difficult
number
symptom
exampl
pain
fever
conjunct
headach
share
infect
upper
respiratori
tract
furthermor
diagnosi
young
children
hamper
child
inabl
describ
symptom
likelihood
distress
experienc
pain
clinic
diagnosi
aom
key
criteria
met
histori
acut
onset
sign
symptom
fever
distinct
otalgia
preclud
normal
activ
sleep
sign
middl
ear
infect
cloudi
bulg
clearli
immobil
eardrum
red
colour
eardrum
presenc
fluid
middl
ear
otorrhoea
clinic
sign
associ
particular
otopathogen
eg
conjunct
associ
h
influenza
sever
case
aom
often
caus
pneumonia
howev
accur
identif
underli
pathogen
possibl
pure
clinic
ground
larg
prospect
finnish
trial
sever
tympan
membran
find
bulg
tympan
membran
spontan
perfor
concomit
high
fever
posit
predict
valu
neg
predict
valu
pneumonia
aetiolog
aom
episod
presenc
purul
conjunct
gave
posit
predict
valu
h
influenza
aom
neg
predict
valu
use
predictor
found
catarrhali
aom
even
absenc
definit
clinic
sign
identif
underli
otopathogen
guidelin
advoc
systemat
use
tympanocentesi
fluid
collect
behind
eardrum
analys
identifi
infecti
organ
involv
perform
antibiot
suscept
test
antibiot
treatment
prescrib
would
chosen
empir
ground
base
local
epidemiolog
data
howev
select
case
antibiot
treatment
failur
complic
aom
essenti
identifi
caus
otopathogen
accur
determin
antibiot
suscept
tympanocentesi
therefor
recommend
order
ensur
effect
treatment
cours
allcaus
aom
incid
peak
age
month
one
studi
report
peak
incid
month
aom
child
month
fig
studi
nthi
show
distinct
pattern
incid
compar
pneumonia
catarrhali
increas
incid
nthi
aom
age
month
peak
month
aom
child
month
moreov
h
influenza
associ
recurr
aom
recov
middl
ear
fluid
mef
first
aom
episod
compar
subsequ
om
episod
first
aom
episod
consid
peak
incid
h
influenza
aom
could
demonstr
children
year
age
despit
use
avail
antibiot
appropri
medic
access
aom
often
lead
recurr
rare
case
sever
intratempor
facial
paralysi
labyrinth
acut
petrosisti
extrem
uncommon
intracrani
complic
mastoid
mening
intracrani
abscess
sinu
thrombosi
although
mastoid
becom
infrequ
industri
countri
incid
childyear
still
common
belief
antibiot
treatment
prescrib
aom
prevent
occurr
prevent
mastoid
systemat
antibiot
treatment
aom
never
establish
mani
factor
account
variat
incid
mastoid
differ
countri
socioeconom
live
condit
antibiot
prescrib
rate
exhaust
epidemiolog
surveil
system
differ
complic
rate
pathogen
inde
bacteri
otopathogen
propens
caus
complic
aom
ga
associ
frequent
sever
complic
mastoid
tabl
sever
complic
h
influenza
uncommon
catarrhali
infect
rare
previous
discuss
evid
suggest
pneumonia
common
sever
episod
om
nthi
commonli
associ
recurr
om
rom
fig
one
recent
studi
assess
underli
microbiolog
rom
defin
three
acut
episod
previou
month
four
past
month
aom
treatment
failur
defin
persist
sign
symptom
aom
h
antibiot
therapi
within
day
complet
antibiot
treatment
cours
us
children
follow
widespread
introduct
although
slight
increas
proport
pneumonia
isol
present
season
h
influenza
frequent
isol
pathogen
isol
across
three
respiratori
season
difficulttotreat
patient
group
time
increas
widespread
use
fig
difficulti
encount
treatment
om
due
exist
antibiot
resist
otopathogen
also
attribut
biofilm
natur
bacteri
om
infect
tabl
risk
develop
mastoid
follow
aom
caus
differ
bacteri
otopathogen
natur
environ
major
bacteria
exist
biofilm
structur
commun
microorgan
embed
within
polymer
matrix
attach
inert
live
surfac
rather
plankton
state
contrast
plankton
bacteria
biofilm
bacteria
character
slow
rate
cell
divis
toler
high
concentr
antibiot
biofilm
infect
therefor
difficult
treat
effect
current
avail
antibiot
agent
reli
rapid
metabol
division
rate
plankton
bacteria
mode
action
presenc
bacteri
biofilm
om
first
suspect
owe
persist
infect
despit
treatment
antibiot
absenc
posit
cell
cultur
specimen
definit
evid
biofilm
natur
om
provid
number
studi
exampl
one
studi
use
polymeras
chain
reaction
techniqu
detect
h
influenza
dna
mrna
mef
children
chronic
om
effus
presenc
shortliv
mrna
molecul
even
absenc
posit
cultur
specimen
indic
presenc
viabl
bacteria
specimen
addit
three
major
bacteri
pathogen
om
proven
form
biofilm
vitro
vivo
one
studi
report
direct
detect
bacteri
biofilm
middl
ear
mucosa
biopsi
children
chronic
om
antibiot
use
result
select
strain
resist
antibiot
demonstr
vitro
pneumonia
alexand
fleme
shortli
discov
penicillin
recent
correl
antibiot
consumpt
resist
demonstr
european
studi
compris
countri
outpati
antibiot
use
correl
resist
antibioticpathogen
combin
specif
pneumonia
nasopharynx
constitut
wide
reservoir
resist
bacteria
pneumonia
also
streptococcu
viridan
h
influenza
catarrhali
easili
select
whenev
antibiot
select
pressur
appli
antibiot
resist
pneumonia
h
influenza
becom
major
public
health
issu
european
union
prioriti
research
action
expect
preval
chronic
obstruct
pulmonari
diseas
increas
come
year
europ
pneumonia
h
influenza
major
infecti
role
condit
similarli
world
health
organ
set
antimicrobi
resist
contain
research
prioriti
particularli
regard
pneumonia
three
major
otopathogen
caus
antibiot
resist
concern
penicillin
multidrug
resist
pneumonia
alreadi
describ
europ
dual
erythromycin
penicillin
nonsuscept
vari
wide
countri
less
amoxicillin
resist
catarrhali
univers
seen
approxim
strain
still
limit
occurr
nthi
mean
product
one
intern
studi
howev
region
franc
usa
japan
southern
asian
region
high
rate
amoxicillin
resist
nthi
sever
mechan
caus
resist
common
product
detect
laboratori
howev
resist
mechan
increasingli
describ
franc
japan
confer
addit
resist
amoxicillinclavulan
cefuroxim
sometim
thirdgener
cephalosporin
usual
investig
routin
microbiolog
recent
studi
conduct
japan
nthi
strain
isol
children
urti
amoxicillin
suscept
produc
other
also
resist
amoxicillinclavulan
variou
degre
cephalosporin
introduct
conjug
vaccin
impact
commens
flora
creat
epidemiolog
nich
altern
potenti
pathogen
includ
vaccin
introduct
usa
result
rapid
shift
microbiolog
om
vaccin
follow
rapid
replac
nonvaccin
pneumonia
serotyp
nasopharynx
vaccin
children
sibl
result
proport
aom
caus
vaccin
serotyp
fallen
diseas
caus
nonvaccin
serotyp
pathogen
nthi
risen
exampl
one
us
studi
signific
increas
percentag
aom
case
due
pneumococc
serogroup
occur
respect
p
howev
declin
observ
penicillin
nonsuscept
pneumonia
strain
mention
previous
multidrugresist
replac
serotyp
may
aris
stress
need
reduc
antibiot
prescrib
order
maxim
benefit
vaccin
elimin
preval
antibioticresist
serotyp
addit
trend
increas
persist
aom
aom
treatment
failur
attribut
h
influenza
observ
singl
us
studi
centr
also
report
three
us
centr
period
om
common
diseas
affect
approxim
three
quarter
children
third
birthday
current
pneumonia
nthi
respons
approxim
bacteri
aom
case
pneumonia
gener
caus
sever
episod
nthi
respons
recurr
episod
underli
microbiolog
om
inher
link
nasopharyng
commens
flora
chang
time
respons
variou
select
pressur
vaccin
use
antibiot
consumpt
consequ
continu
monitor
chang
underli
om
microbiolog
requir
order
provid
effect
prevent
treatment
strategi
combat
common
distress
childhood
diseas
